Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current therapy for malignant melanoma.

S S Legha1

  • 1Department of Medical Oncology, University of Texas MD Anderson Cancer Center, Houston 77030.

Seminars in Oncology
|February 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2006
Same author

Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2001
Same author

A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy.

Cancer·2000
Same author

Uveal melanoma: natural history and treatment options for metastatic disease.

Melanoma research·2000
Same author

Pilot study of intra-arterial cisplatin and intravenous vinblastine and dacarbazine in patients with melanoma in-transit metastases.

Melanoma research·1999
Same author

Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma.

Anti-cancer drugs·1999
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Metastatic melanoma treatment has evolved, with combination chemotherapy and biologic therapies like interferons showing improved response rates over dacarbazine alone. Further controlled trials are needed to confirm the superiority of newer regimens for advanced melanoma.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Stage I melanoma is often curable with surgery, but advanced disease with lymph node involvement or metastasis has a poor prognosis.
  • Current systemic therapies for metastatic melanoma, including dacarbazine (DTIC), have limited efficacy, with response rates around 15-20% and short durations.
  • Adjuvant therapy has shown limited benefit in patients with regional lymph node involvement.

Purpose of the Study:

  • To review the current landscape of systemic and biologic therapies for metastatic melanoma.
  • To evaluate the efficacy and response rates of various chemotherapeutic agents and combination regimens.
  • To assess the role of newer biologic therapies, such as interferons and interleukin-2 (IL-2), in melanoma treatment.

Main Methods:

  • Review of existing literature on melanoma treatment modalities.

Related Experiment Videos

  • Analysis of response rates and survival data for single-agent chemotherapy (DTIC) and combination chemotherapy regimens.
  • Evaluation of clinical trial data for biologic therapies including interferons and IL-2.

    • Main Results:

    • Dacarbazine (DTIC) as a single agent yields response rates of 15-20%, with complete remissions in less than 5% of patients.
    • Combination chemotherapy regimens, particularly those including cisplatin and vinca alkaloids with DTIC, show higher response rates (30-40%) and slightly better complete response rates (approx. 10%).
    • Biologic therapies, such as recombinant alpha interferons, induce tumor regressions in 15-20% of patients and are often used as second-line therapy.

    Conclusions:

    • While combination chemotherapy regimens demonstrate higher response rates than DTIC alone, conclusive evidence of superiority from controlled trials is pending.
    • Biologic therapies offer a viable treatment option for metastatic melanoma, with interferons showing activity in both previously treated and untreated patients.
    • Further research and controlled trials are essential to establish the definitive efficacy of advanced combination chemotherapy and biologic therapies for metastatic melanoma.